Endoglin is a transmembrane glycoprotein that acts as an auxiliary receptor for transforming growth factor-b (TGF-b) and modulates cellular responses to this pleiotropic cytokine. Endoglin is strongly expressed in endothelial cells, where it appears to exert a crucial role in vascular development and angiogenesis. Two endoglin isoforms (L and S), differing in their cytoplasmic domains, have been previously characterized in human tissues. We now demonstrate the existence of similar L-and Sendoglin variants in murine tissues with 47 and 35 amino acids, respectively, in their cytoplasmic tail. RT-PCR analysis showed that L is the predominant endoglin isoform expressed in mouse tissues, although S-endoglin mRNA is significantly expressed in liver and lung, as well as in endothelial cell lines. Furthermore, a protein of size equivalent to recombinant S-endoglin expressed in mammalian cells was detected in mouse endothelial cells by Western blot analysis. L-and S-endoglin isoforms can form disulfide-linked heterodimers, as demonstrated by cotransfection of L-and S-endoglin constructs. To address the role of S-endoglin in vivo, an S-Eng þ transgenic mouse model that targets S-endoglin expression to the endothelium was generated. The lethal phenotype of endoglin-null (Eng À/À ) mice was not rescued by breeding S-Eng þ transgenic mice into the endoglin-null background. S-Eng þ mice exhibited reduced tumor growth and neovascularization after transplantation of Lewis lung carcinoma cells. In addition, S-Eng þ mice showed a drastic inhibition of benign papilloma formation when subjected to two-stage chemical skin carcinogenesis. These results point to S-endoglin as an antiangiogenic molecule, in contrast to L-endoglin which is proangiogenic.
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Introduction
The transforming growth factor-b (TGF-b) family of growth factors, including TGF-b isoforms, activins/ inhibins and bone morphogenetic proteins (BMPs), regulate many fundamental processes, such as cell growth, differentiation, migration, adhesion, angiogenesis and the immune response (Siegel and Massague´, 2003; Waite and Eng, 2003) . TGF-b-related factors transduce their signals by inducing the formation of a heteromeric complex containing specific type I and type II serine/threonine kinase receptors (Letterio and Roberts, 1998; Massague´, 1998) . Two auxiliary membrane receptors, endoglin and betaglycan, can also associate with the TGF-b receptor complex (Massague´, 1998) . Endoglin binds TGF-b 1 , TGF-b 3 , activin-A, BMP-2 and BMP-7 in the presence of the signaling receptors types I and II (Cheifetz et al., 1992; Bellon et al., 1993; Letamendia et al., 1998b; Barbara et al., 1999) , and regulates TGF-b-dependent cellular responses (Lastres et al., 1996; Letamendia et al., 1998b; Li et al., 2000; Diez-Marques et al., 2002) .
Endoglin is predominantly expressed in endothelial cells Letarte, 1988, 1990; Li et al., 2000) , and plays a critical role in vascular development and function, as evidenced by genetic inactivation. The endoglin gene is the target for the vascular disorder known as Hereditary Hemorrhagic Telangiectasia type I (McAllister et al., 1994) ; and endoglin-null (Eng À/À ) murine embryos die of vascular defects at 10-10.5 days postcoitum (Bourdeau et al., 1999; Li et al., 1999; Arthur et al., 2000) . Furthermore, studies on cultured endothelial cells in which endoglin expression was suppressed suggest that it acts as a proangiogenic molecule (Li et al., 2000) . Recently, a role for endoglin as a critical factor in the regulation of nitric oxide-dependent vasodilatation has also been proposed (Jerkic et al., 2004) . Aside from its expression in endothelial cells, endoglin is also present in several nonendothelial tissues, mainly in cellular lineages within the vascular and hematopoietic systems and connective tissues (Fonsatti et al., 2001; Fonsatti and Maio, 2004) . We have shown that endoglin is expressed in the epidermis and skin appendages, such as hair follicles and sweat glands (Quintanilla et al., 2003) . Several tumor cells also express endoglin, including pre-B cell and monocytic leukemia (Quackenbush and Letarte, 1985; Haruta and Seon, 1986; Lastres et al., 1992; Zhang et al., 1996) , choriocarcinoma (Letamendia et al., 1998a) , ovarian carcinoma (Jindal et al., 1995) , melanoma (Altomonte et al., 1996) , prostate cancer (Liu et al., 2002) and basal and squamous cell carcinomas (Quintanilla et al., 2003) . The presence of endoglin in both cells and vasculature of tumors has stimulated studies on the role of endoglin in cancer Takahashi et al., 2001; Duff et al., 2003) . In this respect, recent reports suggest that elevated plasma levels of endoglin in patients with colorectal cancer or breast carcinoma correlate with poor prognosis Duff et al., 2003) .
Endoglin is a disulfide-linked homodimer of 180 kDa, containing a large extracellular domain and a short serine/threonine-rich cytoplasmic region without consensus signaling motifs. This cytoplasmic domain is constitutively phosphorylated on Ser/Thr residues (Lastres et al., 1994; Yamashita et al., 1994) . Molecular cloning of the human endoglin cDNA demonstrated the existence of two protein variants, arising by alternative splicing. L-endoglin, the predominant isoform, has a cytoplasmic domain of 47 residues, whereas the minor isoform, S-endoglin, contains a cytoplasmic tail of only 14 amino acids (Gougos and Letarte, 1990; Bellon et al., 1993) . Both endoglin forms are able to bind ligand (Bellon et al., 1993 ), but differ in their level of phosphorylation (Lastres et al., 1994) , and in their capacity to regulate certain TGF-b-dependent responses (Lastres et al., 1996) . The mouse endoglin homologue of human L-endoglin has also been reported (Ge and Butcher, 1994; St-Jacques et al., 1994) , but the murine S-endoglin form had not been described until now.
TGF-b 1 has both positive and negative effects on carcinogenesis. It may act as a tumor suppressor, early in tumorigenesis, but can also drive malignant progression, invasion and metastasis by distinct mechanisms (see Akhurst and Balmain, 1999; Massague´et al., 2000; Derynck et al., 2001 , Moustakas et al., 2002 , for reviews). TGF-b 1 can act directly on carcinoma cells by inducing an epithelial-mesenchymal transition associated with the development of highly aggressive spindle cell carcinomas (Caulı´n et al., 1995; Oft et al., 1996; Frontelo et al., 1998; Portella et al., 1998) . In addition, TGF-b 1 profoundly affects the tumor microenvironment by acting on several cell types in the proximity to the tumor, including stromal, endothelial and immune cells. Thus, TGF-b has potent immunosuppressive (Torre-Amione et al., 1990; Gorelik and Flavell, 2001) and angiogenic activities (Pertovaara et al., 1994; Hasegawa et al., 2001; Tuxhorn et al., 2002) , creating an environment that facilitates tumor growth, invasion and metastasis. We have recently demonstrated a functional involvement of endoglin in carcinogenesis by using the two-stage chemical skin carcinogenesis mouse model. In this experimental system, treatment of skin with a single dose of a chemical carcinogen, that is, 7,12-dimethylbenz(a)anthracene (DMBA), followed by repeated applications of the tumor promoter 12-Otetradecanoylphorbol-13-acetate (TPA), results in the appearance of multiple benign papillomas, some of which progress to malignant squamous cell carcinomas (SCCs) 20-40 weeks after initiation with the carcinogen (Yuspa, 1994) . Late in carcinogenesis, spindle cell carcinomas (SpCCs) evolve, although at a low frequency (Klein-Szanto et al., 1989) . DMBA/TPA carcinogenesis treatment in endoglin heterozygous (Eng þ /À ) mice resulted in a reduced number of benign tumors compared with normal Eng þ / þ littermates, but progression to highly malignant SpCCs was vastly accelerated (Quintanilla et al., 2003) . This phenotype was identical to that of transgenic mice overexpressing TGF-b 1 in the epidermis (Cui et al., 1996) , suggesting a role for endoglin in tumor formation and malignant progression by attenuating TGF-b signaling.
Here, we have identified for the first time the presence of an S-endoglin isoform in mouse tissues and cultured endothelial cells. We have studied the effects of vascular S-endoglin overexpression on neovascularization and tumor growth by using a transgenic mouse model (SEng þ ) with targeted expression of human S-endoglin under the control of the ICAM-2 endothelial-specific promoter (Velasco et al., 2001) .
Results

Characterization of murine S-endoglin cDNA
To assess the presence of a potential S-endoglin isoform in murine tissues, we designed primers flanking the coding region corresponding to the cytoplasmic tail of the murine protein, according to the published cDNA sequence (St-Jacques et al., 1994) . A 149-bp product of the predicted size plus an additional band of 288-bp were detected by RT-PCR analysis in several mouse keratinocyte cell lines (Figure 1a) . The nucleotide sequence of the lower band was identical to the fragment comprised between nucleotides (nts) 2179 and 2327 of the reported cDNA sequence (St-Jacques et al., 1994) . The larger PCR product of 288 -bp contained a 139-bp segment inserted within the previously known cDNA sequence, starting at nt 2201 (Figure 1b) . The nucleotides of the insert were in frame with the preceding sequence, coding for an additional 28 amino acids prior to a stop codon (TGA). In contrast, a single 1040-bp band of the predicted size and sequence was obtained using oligonucleotides flanking the coding region corresponding to the mouse endoglin ectodomain (Quintanilla et al., 2003) . These results suggest the existence of two alternate forms (L and S) of murine endoglin differing at the cytoplasmic domain, as reported for human endoglin (Bellon et al., 1993) . The mouse S-isoform is 12 residues shorter and conserves a juxtamembrane cluster of seven amino acids, plus a Lys and a Pro within the endodomain when compared to L-endoglin ( Figure 1c , left panel). S-endoglin lacks a Class I PDZ-binding motif (SSMA), which is present at the carboxyl terminus of both L-endoglin and betaglycan. This sequence was reported to be important for stabilization of betaglycan at the cell surface (Blobe et al., 2001) . Mouse S-endoglin also lacks a Ser-616, conserved in mouse and human L-endoglin, and identified as a potential phosphorylation site (RGPSKR) for protein kinase C (Lastres et al., 1994) . The cytoplasmic domains of mouse and human S-endoglin share an almost identical sequence of 14 amino acids containing a proline-rich sequence (PxPP, see Figure 1c , right panel) reported to be a recognition The 139-bp insert within the S-endoglin mRNA identified in this work corresponds to the intron located between exons 14 and 15 (asterisk). This region is transcribed into the S-endoglin mRNA. The presence of consensus sequences for the splicing machinery within this fragment suggest that it is spliced out to yield the L-endoglin mRNA, as shown by the nucleotide sequence of the 149-bp mRNA product expressed in mouse keratinocytes site for SH3 domains (Kay et al., 2000) . The mouse S endodomain is 21 residues larger than the human, but this extra C-terminal sequence characteristic of the mouse S isoform does not contain obvious consensus motifs, except a Ser-624 presumed to be a potential protein kinase C-dependent phosphorylation site, and Ser-627 and Thr-637 predicted to be phosphorylated by casein kinase-1. According to the available mouse genomic database at National Cancer for Biotechnology Information (NCBI), it can be deduced that the mouse endoglin gene contains 15 exons and 14 introns. In light of the present work, the predicted intron lying between exons 14 and 15 is transcribed into the S-endoglin mRNA, but generally spliced out to yield the L-endoglin transcript ( Figure 1d ).
Expression of L-and S-endoglin in mouse tissues and cell lines
RT-PCR analysis using specific primers to amplify L-and S-endoglin mRNAs individually (bands of 160 and 140 bp, respectively, Figure 2a , b) or common primers to simultaneously amplify a 288-bp S-endoglin and a 149-bp L-endoglin mRNA fragments in the same reaction ( Figure 2c ) showed that the short isoform is expressed in several mouse tissues, such as liver and lung, while its level of expression was much less in heart, spleen and epidermis (Figure 2a, c) . In contrast, the levels of L-endoglin mRNA were fairly constant in all analysed tissues. We also studied the expression of L-and S-endoglin mRNAs in mouse cultured cells (Figure 2b, c) , including fibroblast (NIH3T3, L929), endothelial (MS-1, EOMA) and epidermal (MCA3D, Pam 212, PB, HaCa-4, PDV, Car B and Car C) cell lines. As found in the epidermis in vivo, predominance of L-endoglin was, in general, maintained in premalignant (MCA3D, PB) and malignant (HaCa 4, PDV, Car C and Car B) epidermal cell lines. The only exception was the transformed keratinocyte cell line Pam 212, which expressed a substantial level of S-endoglin mRNA (see also Figure 1a ). Significant levels of S-endoglin mRNA were also detected in L929 (but not in NIH3T3) fibroblasts, and in both immortalized (MS-1) and transformed (EOMA) endothelial cells.
To further characterize murine L-and S-endoglin proteins, and to compare their sizes with that of the corresponding human endoglin forms, independent constructs encoding mouse or human L-and S-endoglin isoforms were subcloned into the pcDNA3 expression vector and transfected into 293T cells. Bands of distinct size (of about 180 and 160 kDa) were detected under nonreducing conditions for mouse L-and S-endoglin, respectively (Figure 3a) , suggesting that both isoforms are expressed as disulfide-linked homodimers, as demonstrated for human L-and S-endoglin (Bellon et al., 1993) . In fact, molecular masses of about 87 -kDa (Lendoglin) and 81 kDa (S-endoglin), slightly lower than that of the corresponding human isoforms, were detected for mouse endoglin by Western blotting under reducing conditions (Figure 3b ). We also compared the sizes of the exogenous proteins with that of endogenous endoglin proteins synthesized by murine L929 fibroblasts and MS1 and EOMA endothelial cells, all of which express S-endoglin transcripts (see Figure 2b , c). As shown in Figure 3b , a doublet was detected in endothelial MS1 and EOMA cells with similar molecular masses as that of exogenous murine L-and S-endoglin, while only a highly intense band corresponding to L-endoglin was observed in L929 fibroblasts. This result raises the possibility that murine endothelial cells can synthesize significant amounts of the short isoform together with L-endoglin. The absence of antibody reacting exclusively with mouse S-endoglin renders difficult its confirmation as an endogenous protein. Assuming that both L-and S-endoglin forms coexist in endothelial cells, we analysed whether they can be expressed as heterodimers. To this aim, 293T cells were cotransfected with L-and S-endoglin constructs tagged with HA and Flag, respectively. Immunoprecipitation analysis with anti-HA or anti-Flag antibodies demonstrated that each isoform coprecipitated with the other (Figure 3c ), suggesting that L-can associate with S-endoglin when both are expressed in the same cell. To investigate whether the cytoplasmic domain was involved in the heteromeric association between L-and S-endoglin, we used a HA-TMCT-L-endoglin construct encoding a truncated L-endoglin product which lacks most of the extracellular domain (Guerrero-Esteo et al., (Bourdeau et al., 1999; Li et al., 1999; Arthur et al., 2000) . To determine the effect of S-endoglin on the vascular-specific rescue of this lethal phenotype, we took advantage of a previously generated transgenic line of mice (S-Eng þ ) overexpressing human S-endoglin on the vascular endothelium driven by the ICAM-2 promoter. The S-Eng þ mice are fertile, show a normal ratio of male to female littermates and have no specific susceptibility to disease (Velasco et al., 2001) . The endoglin heterozygous (Eng Retardation of tumor growth and reduced incidence of chemically induced skin papillomas in S-Eng þ transgenic mice Although blood vessel formation during embryonic development and in the vasculature of adult animals were apparently normal in S-Eng þ transgenic mice (Velasco et al., 2001) , we analysed whether these mice showed an altered angiogenic tumor phenotype. To this aim, we compared the growth and vascularization of tumors induced in S-Eng þ and control mice upon s.c. injection of Lewis lung carcinoma (3LL) cells, a widely used in vivo model for tumor angiogenesis and metastatic infiltration (Portella et al., 2003) . The weight of tumors induced in S-Eng þ mice was about 35% lower than in control mice (Figure 5a ). The amounts of DNA and protein per mg of tissue were the same in tumors of both mouse lines (Figure 5c, d ), indicating that differences in tumor weight were not due to tisular edema or cell hypertrophy. Strikingly, the hemoglobin content, an index of tumor vascularization, was about 65% lower in tumors induced in S-Eng þ than in tumors of control mice (Figure 5b ), suggesting that S-Eng þ tumors grew more slowly due to a deficient angiogenic response.
We also studied the effect of vascular expression of S-endoglin on chemically induced skin tumors, using a standard two-step chemical carcinogenesis protocol with DMBA for tumor initiation and TPA for promotion of tumor growth. We have previously used this experimental model to characterize the biological role of endogenous endoglin on multistage skin carcinogenesis using Eng þ /À heterozygous mice (Quintanilla et al., 2003) . Two independent experiments were performed, in which groups of S-Eng þ , Eng þ /À (only in experiment 2) Mice from the indicated lines were crossed and the progeny genotyped as described in Materials and methods
Figure 4
Genotyping of genetically modified mice. (a) Genotypes of Eng þ /À or Eng þ / þ mice determined by PCR analysis of tail DNA using two sets of primers amplifying a 470-bp fragment in the mutated allele, and a 300-bp product in the wild-type allele. M, molecular weight markers. (b) Transgenic S-Eng þ animals were genotyped by PCR analysis of tail DNA using two sets of primers amplifying a 300-bp product for wild-type endoglin, and a 604-bp product for the transgen. C, expression vector and control Eng þ / þ mice were treated with an initial dose of DMBA followed by twice weekly applications of TPA for 20 weeks. A significant reduction in the number of tumors per mouse (2-3-fold) was observed in the S-Eng þ and Eng þ /À groups, with respect to Eng þ / þ mice, throughout the observation period (Figure 6 ). At the end of the experiments, all tumors of control mice were histologically typed as benign papillomas (Table 2) . Only one tumor in S-Eng þ mice (experiment 1) exhibited characteristics of a malignant SCC. Nevertheless, this moderately differentiated carcinoma developed from three close papillomas that fused together between weeks 15 and 16 postinitiation. In contrast, most tumors (five out of seven) in Eng þ /À mice were malignant SCCs, with differentiation grades ranging from moderately to poorly differentiated (Table 2) , as previously reported (Quintanilla et al., 2003) . These results suggest that overexpression of S-endoglin in vascular endothelial cells reduces tumor incidence but does not significantly affect the frequency of malignant conversion.
Discussion
We demonstrate in this report the existence of two alternate endoglin variants (L and S) in mouse tissues. These two isoforms presumably originate by an alternate splicing whereby the predicted intron 14 of the endoglin gene is retained into the S-endoglin mRNA and spliced out to yield the L-endoglin transcript, as postulated for human endoglin (Bellon et al., 1993) . Mouse S-endoglin is 12 residues shorter than L-endoglin and greatly differs from it in the amino-acid composition of the cytoplasmic tail. A comparison between human and mouse S-endoglin reveals than the latter has an extra C-terminal 21 amino-acid sequence containing two Ser and one Thr that are potential phosphorylation sites for protein kinase C or casein kinase-1. Whether these putative phosphorylation residues present in mouse S-, but absent from human S-endoglin are functionally relevant remains to be investigated. Although L-appears to be the predominant endoglin transcript expressed in mouse tissues and cell lines, significant levels of S-endoglin mRNA are coexpressed with L-endoglin in several tissues, such as liver and lung, as well as in endothelial cultured cells. A protein of size identical to that of S-endoglin was detected in two murine endothelial cell lines by Western blotting, suggesting that both L-and S-endoglin isoforms could be synthesized in blood vessels. Both human L-and S-endoglin proteins form disulfide-linked homodimers at the cell surface (Gougos and Letarte, 1990; Bellon et al., 1993) , at least through the Cys-582 residue present in the extracellular domain (Guerrero-Esteo et al., 2002) . Furthermore, interspecies dimerization has been found between human and mouse L-endoglin (Raab et al., 1999) . Here we show by transfection of 293T cells with HA-and Flag-tagged L-and S-endoglin constructs that L-and S-endoglin interact to form heterodimers through covalent linkage of the common extracellular domains. Therefore, in cells in which both isoforms are cosynthesized, the presence of L-S heterodimers, in addition to L-L and S-S homodimers, would add a new level of functional complexity to the endoglin molecule. In this respect, it is tempting to speculate that the ability to modulate TGF-b responses, as a result of the interaction of the L and S cytoplasmic domains with TGF-b receptors (Guerrero-Esteo et al., 2002) , or the association with cytoskeletal components (Conley et al., 2004; Sanz-Rodriguez et al., 2004) would be different for the distinct endoglin dimers.
Endoglin is upregulated in angiogenic endothelial cells, and several studies suggest that it is required for angiogenesis (reviewed in Li et al., 2001; Duff et al., 2003) . A key evidence for the important role of endoglin in angiogenesis comes from studies on Eng À/À mice. These mice die at an early embryonic stage due to defective formation of mature blood vessels and arrested heart development (Bourdeau et al., 1999; Li et al., 1999; Arthur et al., 2000) . In the current study, we demonstrated that vascular expression of S-endoglin cannot rescue the lethal phenotype of Eng À/À mice, and therefore cannot substitute for L-endoglin function in endothelial cells. Induction of angiogenesis is considered essential not only for growth and dissemination of cancer but also for tumor formation (Hanahan and Folkman, 1996) . The causal role of angiogenesis in cancer has been assessed in vivo using animal models, including both traditional tumor transplants and mouse models of multistage carcinogenesis. From the latter, it is thought that neovascularization is first activated by an 'angiogenic switch' during premalignant phases of carcinogenesis, before tumors emerge (Folkman et al., 1989; Hanahan and Folkman, 1996; Bolontrade et al., 1998; Huss et al., 2001) . Using the 3LL transplantation model, we found that S-Eng þ mice exhibit a deficient angiogenic phenotype leading to retardation of tumor growth. In addition, we have tested the effect of vascular expression of Sendoglin on tumor formation and malignant progression during chemical mouse skin carcinogenesis. Our results clearly demonstrate that overexpression of S-endoglin in endothelial cells inhibits benign tumor formation without significantly affecting the conversion of papillomas to malignant SCCs. In contrast, endoglin haploinsufficiency, as exemplified by heterozygous Eng þ /À mice, has a dual effect in mouse skin carcinogenesis, inhibiting the early appearance of tumors to the same extent as in S-Eng þ mice, but accelerating malignant conversion (Quintanilla et al., 2003) . Recent studies from some of the laboratories involved in this work show that Eng þ /À mice also exhibit The initial number of animals in this group was eight. However, a S-Eng + mouse was removed from the study at week 9 postinitiation after developing a huge skin ulceration on the back Figure 6 Rate of appearance of skin tumors in S-Eng þ , Eng
and Eng þ / þ mice. In experiment one, 10 and seven animals were used in Eng þ / þ and S-Eng þ groups, respectively. In experiment two, seven animals were used in each group. The average number of tumors (over 2 mm in diameter) is plotted versus the number of weeks after initiation with DMBA. Data from S-Eng þ and Eng þ /À mice were compared versus Eng þ / þ mice by the Student t-test (*Po0.05, **Po0.01) defective tumoral and postischemic angiogenesis (Jerkic M and Ló pez-Novoa JM, manuscript in preparation). Therefore, impaired angiogenesis could account for the decreased skin papilloma formation in both Eng þ /À and S-Eng þ mice. Nevertheless, accelerated conversion from papillomas to poorly differentiated SCCs in Eng þ /À mice cannot be attributed to impaired angiogenesis, and suggests an anti-invasive role for endoglin in mouse skin carcinogenesis. We have postulated that endoglin haploinsufficiency could enhance the malignant promoting activity of TGF-b 1 in tumor cells (Quintanilla et al., 2003) , since endoglin inhibits several TGF-b 1 -dependent cellular responses (Lastres et al., 1996; Letamendia et al., 1998b; Diez-Marques et al., 2002) , and transgenic mice overexpressing TGF-b 1 in the epidermis exhibited a similar phenotype to that of Eng þ /À mice when subjected to chemical carcinogenesis treatment (Cui et al., 1996) . Thus, the complex tumoral phenotype of Eng þ /À mice could implicate an intrincate network of cellular responses involving keratinocytes and endothelial cells.
According to the results presented in this work, S-endoglin appears to behave as an antiangiogenic molecule, in contrast to L-endoglin which is proangiogenic (Li et al., 2000) . We speculate that overexpression of S-endoglin in endothelial cells could interfere in the interaction of L-L homodimers with TGF-b receptors, by competing its association through the extracellular domain and by sequestering L-endoglin in L-S heterodimers. Further experimental evidence is required to confirm this hypothesis.
Materials and methods
Cell lines and culture conditions
The origin of mouse epidermal cell lines (MCA3D, Pam 212, PB, HaCa-4, PDV, Car B and Car C) has been described elsewhere (Quintanilla et al., 2003) . Murine immortalized endothelial MS-1 (Arbiser et al., 1997) and hemangioendothelioma-derived EOMA (Obeso et al., 1990) cell lines were kindly provided by Dr B Jime´nez (Instituto de Investigaciones Biome´dicas CSIC-UAM, Madrid, Spain). Human embryo kidney HEK-293T cells and 3LL Lewis lung carcinoma cells were a generous gift from Dr A Cano (Instituto de Investigaciones Biome´dicas CSIC-UAM, Madrid, Spain) and Dr S Alin˜o (Departamento de Farmacologia, Universidad de Valencia, Valencia, Spain), respectively. NIH3T3 and L929 fibroblasts were obtained from the American Type Culture Collection (Rockville, MD, USA). Cell lines were grown in Ham's F12 medium supplemented with amino acids and vitamins (MCA3D, PB, PDV, HaCa4 and Car B) or Dulbecco's modified Eagle's medium (Pam212, Car C, NIH3T3, L929, MS1, EOMA and 293T), with 10% fetal calf serum (Gibco Invitrogen Corp., Barcelona, Spain) and antibiotics (25 mg/ml amphotericin B, 100 mg/ml ampicillin and 32 mg/ml gentamicin; Sigma-Aldrich, Madrid, Spain). Cultures were maintained at 371C in a 5% CO 2 humidified atmosphere.
RT-PCR and Western blot analysis
For RT-PCR analysis, RNA samples (1 mg) isolated from mouse tissues and cell lines by the guanidinium thiocyanate procedure were incubated with the Moloney murine leukemia virus reverse transcriptase (Promega Corp., Madison, WI, USA), and the generated cDNAs were used for PCR amplification. For identification of the S-endoglin cDNA in mouse keratinocyte lines, the following oligonucleotides were used to amplify a 3 0 mRNA fragment, based on the previously reported mouse endoglin cDNA sequence (St-Jacques et al., 1994) : 5 0 -TGGTACATCTATTCTCACACAC-3 0 (nucleotides 2179-2200) and 5 0 -CACTACGCCATGCTGCTGGTGG-3 0 (nucleotides 2306-2327). PCR conditions were 35 cycles: 951C for 1 min, 581C for 40 s, 721C for 1 min. PCR products were fractionated in 1% agarose-ethidium bromide gels. The 288 and 149-bp fragments obtained were isolated using a gel extraction kit (QIAquick; QuiagenGmbH, Hilden, Germany) and sequenced in an ABI PRISM 377 machine (PE Applied Biosystems, Foster City, CA, USA). The 288-bp PCR product contained a 139-bp segment inserted within the previously known cDNA sequence after nt 2200, yielding the S-endoglin cDNA sequence. For individual amplification of L-and Sendoglin mRNAs, we used oligonucleotides flanking the coding sequence corresponding to the cytoplasmic domains of each isoform. For L-endoglin, the following primers were used: 5 0 -GCACTCTGGTACATCTATTCTCACACACGT GG-3 0 (nucleotides 2173-2230) and 5 0 -GGGCACTACGCCA TGCTGCTGGTGG-3 0 (nucleotides 2306-2330), according to the sequence reported by St-Jacques et al. (1994) . For S-endoglin, the following primers were used: 5 0 -TGAGTATC CCAAGCCTCCACCCCAT-3 0 (nucleotides 2202-2226) and 5 0 -CTGAGGGGCGTGGGTGAAGGTCAG-3 0 (nucleotides 2316-2339), according to the sequence presented in Figure 1 . PCR conditions were 35 cycles: 951C for 1 min, 651C for 30 s, 721C for 5 s.
For detection of endoglin in Western blots, cells were lysed as previously described (Quintanilla et al., 2003) . Lysates were fractionated by 7.5% SDS-PAGE under nonreducing or reducing conditions and electrotransferred to Immobilon P membranes (Millipore Corp., Bedford, MA, USA). For immunodetection of endoglin proteins, the mAbs MJ7/18 (Ge and Butcher, 1994) and P4A4 (Pichuantes et al., 1997) , which recognize epitopes within the extracellular domains of murine and human endoglin, respectively, were used with appropriate secondary Abs coupled to horseradish peroxidase. The peroxidase activity was developed using an enhanced chemiluminescence kit (Amersham Biosciences, Barcelona, Spain).
Expression vectors
The cDNAs encoding full-length murine L-and S-endoglin polypeptides were cloned by RT-PCR from L929 fibroblasts. For S-endoglin, the primers used were A (5 0 -AGCGCACAG ACTCCCGGGTGGACAGC-3 0 ; nucleotides 338-364) and B (5 0 -GCCCCAGCCAGGACTCCCCGCTTCTT-3 0 ; nucleotides 2289-2315). The primers used for L-endoglin were A and C (5 0 -CGAGGCTCCAGGCTGGGCACTACGCC-3 0 ; nucleotides 2458-2484). PCR conditions were 35 cycles: 951C for 1 min, 631C for 2 min, 721C for 3 min. The set of primers A-B amplified a single 1977-bp product comprising the coding region of murine S-endoglin, with the ATG start codon at position 364 (St-Jacques et al., 1994) and the TGA stop codon at position 2287, as determined by sequencing. The set of primers A-C amplified two products of 2146 and 2007 -bp. The smaller cDNA fragment was selected and found to contain the entire coding region of L-endoglin (without the 139-bp insert), including the ATG start codon and the TAG stop codon at position 2462. These cDNAs were subcloned into the pcDNA3 expression vector (InVitrogen, San Diego, CA, USA). The full-length cDNAs encoding human L-or Sendoglin, cloned in pcEXV vector (Lastres et al., 1996) , were also subcloned into the pcDNA3 expression vector. The TMCT-L-endoglin construct, encoding a truncated human L-endoglin product, which lacks the extracellular domain, and the wild-type human L-endoglin construct, both tagged with the influenza hemagglutinin (HA) epitope, subcloned into the pDisplay vector, were previously described (Guerrero-Esteo et al., 2002) . The cDNA construct encoding wild-type human S-endoglin fused to the epitope Flag was obtained by amplifying the S-endoglin cDNA, using the following primers: 5 0 -GCACAGAATTCCACGTGGACAGCATGGACCGC-3 0 (nucleotides 326-358) and 5 0 -CGGCATGGTACCTGTGGG GGCCTGGGGTACTCACG-3 0 (nucleotides 2200-2235). PCR conditions were 35 cycles: 951C for 1 min, 631C for 2 min, 721C for 3 min. The product was subcloned into a pcDNA3 expression vector which fused the Flag epitope in the 3 0 end (pcDNA3-Flag).
Transfection and co-immunoprecipitation experiments
HEK-293T cells were transiently transfected with expression vectors using LipofectAMINE Plus, as indicated by the manufacturer (InVitrogen S.A., Barcelona, Spain). Cells were lysed 24 h after transfection and protein expression determined by Western blotting or co-immunoprecipitation. For immunoprecipitation experiments, cells were lysed in IP buffer (1% Triton X-100, 25 mM HEPES, pH 7.5, 100 mM NaCl, 5 mM EDTA, 10% glycerol) and a cocktail of protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 2 mM iodoacetic acid and 2 mM N-ethylmaleimide), and tagged endoglin proteins immunoprecipitated using anti-HA (clone 3F10, Roche Diagnostics S.L., St Cugat del Valle´s, Spain) or anti-Flag (Sigma-Aldrich) mAbs. Rabbit anti-rat or anti-mouse IgGs (Jackson Immunoresearch, West Grove, PA) coupled to protein A-Sepharose, were used as secondary Abs. Detection of co-precipitated endoglin protein isoforms in Western blots was performed with anti-HA and anti-Flag mAbs.
Rescue experiment with genetically modified mice
Transgenic mice expressing the human S-endoglin cDNA under the control of the endothelial-specific promoter ICAM-2 (S-Eng þ mice) have been previously described (Velasco et al., 2001) . Briefly, transgenic mice were obtained from microinjection of the pICAM-2/S-Eng construct into fertilized C57Bl/ 6xSJL mouse embryos. Mice heterozygous for the endoglin gene (Eng þ /À ; 129/OlaxC57Bl/6) previously developed (Bourdeau et al., 1999) were backcrossed at least five times with C57Bl/6 mice (Rodriguez-Pen˜a et al., 2002) . Then, Eng þ /À mice were intercrossed with S-Eng þ mice to obtain mice that lack one copy of the endoglin gene and contained the transgene (Eng þ /À ;S-Eng þ ). Next, these Eng þ /À ;S-Eng þ mice were mated and offspring genotyped by PCR analysis of tail DNA. A total of six male and four female Eng þ /À ;S-Eng þ mice, which gave rise to 13 litters and 77 puppies, were used. Genotyping for the heterozygous or homozygous endoglin knockout was performed using two sets of primers amplifying a 470-bp product in the mutated allele, and a 300-bp product in the wild-type allele (Bourdeau et al., 1999) . Transgenic animals heterozygous for the human S-endoglin gene were genotyped using two sets of primers amplifying a 300-bp product for the endogenous mouse endoglin, and a 604-bp product for the transgene. As controls, heterozygous Eng þ /À mice were mated, and transgenic S-Eng þ mice were crossed with normal mice.
Tumor assay
Exponentially growing 3LL cells were collected and injected s.c. into the dorsum of S-Eng þ transgenic mice or normal littermates (nine animals each). Approximately 10 6 cells were used for a single injection in each animal. At 9 days after 3LL inoculation, mice were anesthetized with ether and tumors removed, weighted and immediately frozen for hemoglobin, DNA and protein determinations. Hemoglobin was measured by spectrophotometry using the Drabkin method. Tumor tissue was homogenized in Drabkin's reagent (Sigma-Aldrich), and centrifuged at 12 000 g for 10 min. Hemoglobin released in the supernatant was measured at 595 nm. DNA content was determined using the diphenylamine reaction. Tumor tissue was homogenized in lysis buffer (10 mM Tris-HCL, pH 8,0, 20 mM EDTA, 0.5% Triton X-100, 0.5% SDS), sonicated three times for 5 s, and centrifuged at 12 000 g for 10 min. Part of the supernatant was mixed with the same volume of 20% perchloric acid, incubated for 15 min at 801C, cooled down to room temperature for 15 min, and, then, incubated with diphenylamine reagent (0.01% paraldehyde, 240 mM diphenylamine in glacial acetic acid) overnight. DNA content was measured at 720 versus 595 nm. Protein content was determined using the Bio-Rad Dc protein assay (Bio-Rad Laboratories SA, Madrid, Spain).
Chemical carcinogenesis
Tumors were induced on the shaved dorsal skin of 10-week-old S-Eng þ , Eng þ /À and control mice by topical application of a single dose of 32 mg of DMBA (in 200 ml of acetone), followed by treatment twice a week with 12.5 mg of TPA (in 200 ml of acetone) for 20 weeks, as previously described (Quintanilla et al., 2003) . The number of tumors (>2 mm in diameter) was recorded weekly. At the end of the experiments, mice were anesthetized and killed, and tumors were fixed in formalin and embedded in paraffin. The tumors were histologically typed by hematoxylin and eosin staining of paraffin sections.
